The transparency discussion is undermined by the fixation on outcomes and the focus on publishing information that realistically adds almost nothing to the community's understanding of how medicines are funded in Australia. This fixation is compounded by a power imbalance that sees all the pressure on the industry when it comes to transparency while 'backroom' processes remain a mysterious locked box.
Transparency of process is more important than transparency of outcome
January 23, 2020 Latest NewsCommentNews of the Day
Latest Video
New Stories
-
A hearing that provided more evidence of the need for meaningful change
October 29, 2026 - - Latest News -
Biotech sector warns R&D tax changes could drive clinical trials offshore
October 28, 2026 - - Latest News -
Rebates and net spend are the major PBS story of the past decade
October 28, 2026 - - Latest News -
Astellas bets up to US$1.34 billion on Melbourne startup's cancer candidate
October 28, 2026 - - Latest News -
Managing an agreement negotiation as a 'prisoner of circumstance'
October 28, 2026 - - Latest News -
Lung scarring killing 11 Australians a day, with one in five cases traced to work
October 28, 2026 - - Latest News -
The stakes are very high on access in a contested budget environment
October 28, 2026 - - Latest News
